Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biogen 1Q Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Biogen 1Q Results

Multiple sclerosis portfolio sales and rare disease revenue down 4% in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen
1Q Revenues: $2.3 billion (-7%)
1Q Earnings: $393.4 million (+1%)
Comments: Multiple sclerosis (MS) product revenue, which includes TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA, was $1.1 billion, down 4%. Rare disease revenue, which includes SPINRAZA, QALSODY and SKYCLARYS, was $424 million in the quarter, down 4%. Biosimilars revenue was $197 million, up 2%. Contract manufacturing, royalty and other revenue was down 39% to $185 million. LEQEMBI launch uptake accelerated in the quarter with sales of approximately $19 million, nearly triple than 4Q23. SKYCLARYS first quarter global revenue was $78 million with the U.S. and EU launch now underway.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters